The regulatory capture of 'neutral' institutions like the FDA by BP makes it extremely difficult for new entrants to succeed without giving BP a cut. NP should've just let one of the BP's have their cut with CYDY instead of holding out. At least we would've gotten ours instead of crying how no one will take us to the 'CV-19 therapeutic celebration party'. Well, we're where we're at now so I say NP should let this play out. See if the good results from m2m and s/c are enough to make CYDY rise above BPs efforts. I am hopeful, but doubtful.